Ratings by Leerink Partners (Thomas J. Smith)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/9/2025 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2024 | Aclaris Therapeutis | ACRS | Upgrade | Outperform (Market Perform) |
3.14 (3.06) |
-2.55% | Details | |
| 11/1/2024 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2024 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2024 | Alpine Immune Sciences | ALPN | Downgrade | Market Perform (Outperform) |
47.04 (64.97) |
38.12% | Details | |
| 3/25/2024 | Sagimet Biosciences Inc | SGMT | New Coverage | Outperform (N/A) |
4.51 (5.41) |
19.96% | Details | |
| 2/20/2024 | CymaBay Therapeutic | CBAY | Downgrade | Market Perform (Outperform) |
32.20 (32.48) |
0.87% | Details | |
| 11/13/2023 | Aclaris Therapeutis | ACRS | Downgrade | Market Perform (Outperform) |
4.76 (3.14) |
-34.03% | Details | |
| 9/12/2023 | Moonlake Immunotherapeutics | MLTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2023 | CymaBay Therapeutic | CBAY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2022 | Alpine Immune Sciences | ALPN | New Coverage | Outperform (N/A) |
6.55 (64.97) |
891.91% | Details | |
| 10/21/2022 | Immunic Inc. | IMUX | Downgrade | Market Perform (Outperform) |
9.20 (1.23) |
-86.63% | Details | |
| 8/25/2022 | Moonlake Immunotherapeutics | MLTX | New Coverage | Outperform (N/A) |
9.01 (18.15) |
101.44% | Details | |
| 12/7/2021 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2021 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/6/2021 | Intercept Pharmaceuticals | ICPT | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/6/2020 | CymaBay Therapeutic | CBAY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2020 | Aclaris Therapeutis | ACRS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2020 | CymaBay Therapeutic | CBAY | Maintain | Outperform (N/A) |
|
Details |
